Edgewise Therapeutics doses first patient in Phase 2 EDG-15400 HFpEF trialPUBT·Oct 8, 2026 at 12:02 PMEWTX-1.01%
Edgewise Therapeutics (EWTX) Could Be 20% Undervalued After Its EDG 7500 Investor CallSimplywall·Oct 3, 2026 at 11:21 AMEWTX-1.01%
Edgewise Therapeutics grants inducement equity awards covering 11,251 shares to three new employeesPUBT·Oct 1, 2026 at 12:01 PMEWTX-1.01%
EWTX: EDG-7500 shows promise for HCM, preserving systolic function and improving diastolic relaxationQuartr·Sep 22, 2026 at 12:56 PMEWTX-1.01%
Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathyPUBT·Sep 22, 2026 at 11:01 AMEWTX-1.01%
Edgewise Therapeutics grants inducement equity awards covering 31,501 shares to new hiresPUBT·Sep 2, 2026 at 12:00 PMEWTX-1.01%
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 | EWTX Stock NewsStockTitan·Aug 24, 2026 at 04:00 AMEWTX-1.01%
The Algorithm's Leftovers: What 10 Unclassified Stocks Reveal About the MarketGlobal Report·Aug 18, 2026 at 10:12 AMHAPN+0.99%COOT+1.97%
Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) StockMarket Beat·Aug 14, 2026 at 09:22 PMEWTX-1.01%
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in StockMarket Beat·Aug 14, 2026 at 09:08 PMEWTX-1.01%
